HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

J&J To End Johnson’s Baby Powder Sales In North American Markets, But Maintains Safety Convictions

Executive Summary

The iconic talc-based product will no longer be available for purchase in the US and Canada after supplies run out. Standing firm on the safety of Johnson’s Baby Powder, J&J attributes the move to declining demand due to changing consumer habits, misinformation “and a constant barrage of litigation advertising.”

You may also be interested in...



J&J Pulls Plug On Talc Across Its Baby Powder Portfolio, Shifts To Cornstarch-Based Products

As it did when it halted sales in US and Canada in 2020, J&J’s latest announcement attributes its decision as coming from a “portfolio assessment” and stated it remains confident in using talc in baby powder and cosmetics.

J&J Consumer Health Q2 Results No Help For Avoiding Lowering Full-Year Guidance Again

J&J reported lower consumer health sales during its latest quarter; consumer health businesses name and branding to be announced in the next few months.

Proposal For J&J To Halt Talc Powder Sales Worldwide Fails In Shareholder Vote

Activist investment group Tulipshare’s proposal that J&J fully cease sales of talc-based powders didn’t receive a majority of votes in favor during firm's annual meeting and won’t be forwarded for board’s consideration. Separate proposal for an audit into whether firm marketed products to minority women asbestos concerns was sent to the board.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

RS150049

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel